Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000030151
Abstract: Purpose: To elucidate the relationship between peripheral edema and programmed cell death-1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors, the meta-analysis was performed. Method: Following the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-analyses,… read more here.
Keywords: edema; incidence risk; analysis; chemotherapy ... See more keywords
Capmatinib successfully overcomes tepotinib-induced intolerable peripheral edema.
Sign Up to like & getrecommendations! Published in 2021 at "Thoracic cancer"
DOI: 10.1111/1759-7714.14205
Abstract: In May 2020 and February 2021, capmatinib and tepotinib, respectively were approved by the Food and Drug Administration (FDA) for the treatment of metastatic non-small cell lung carcinoma harboring mesenchymal-epithelial transition (MET) exon 14 skipping… read more here.
Keywords: intolerable peripheral; capmatinib successfully; peripheral edema; edema ... See more keywords
Higher vascularity at infiltrated peripheral edema differentiates proneural glioblastoma subtype
Sign Up to like & getrecommendations! Published in 2020 at "PLoS ONE"
DOI: 10.1371/journal.pone.0232500
Abstract: Background and purpose Genetic classifications are crucial for understanding the heterogeneity of glioblastoma. Recently, perfusion MRI techniques have demonstrated associations molecular alterations. In this work, we investigated whether perfusion markers within infiltrated peripheral edema were… read more here.
Keywords: peripheral edema; infiltrated peripheral; proneural glioblastoma; subtype ... See more keywords
Combined Use of Calcium-channel Blockers With Ombitasvir/Paritaprevir/Ritonavir Exacerbates Peripheral Edema in Elderly Japanese Patients
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.15690
Abstract: Background/Aim: The antiviral agent ritonavir is a substrate for cytochrome P450 3A4 (CYP3A4); therefore, concomitant use of CYP3A4-metabolising drugs might cause adverse reactions to this drug. We investigated the plasma level of calcium channel blockers… read more here.
Keywords: peripheral edema; ombitasvir paritaprevir; ritonavir; channel blockers ... See more keywords